Eli Lilly and Company (NYSE:LLY) Stock Upgrade
Credit Suisse upgraded shares of Eli Lilly and Company (NYSE:LLY) from a “Neutral” rating to a solid “Outperform” rating in a recent research report revealed on Tuesday, 8 December. The brokerage now has a $105.00 PT on shares.
From a total of 19 analysts covering Eli Lilly and Company (NYSE:LLY) stock, 14 rate it a ”Buy”, 0 a “Sell”, and 7 a ”Hold”. This means that 67% of the ratings are positive. The highest target price is $125 while the lowest target price is $82. The mean of all analyst targets is $99 with a 16.54% above today’s ($86.4) stock price. Eli Lilly and Company was the topic of 25 analyst reports since July 23, 2015 according to the firm StockzIntelligence Inc. Credit Suisse upgraded shares on December 8 to “Outperform” rating. Cowen & Co maintained shares with “Outperform” rating and $92 target share price in a report from an August 24. Barclays Capital upgraded LLY stock in a recent report from December 1 to “Overweight” rating. Finally, Leerink Swann maintained the stock with “Outperform” rating in a report issued on a November 12.
The stock increased 0.02% or $0.02 during the last trading session, striking $86.4. Approximately shares of stock traded hands. Eli Lilly and Co (NYSE:LLY) has risen 19.93% since May 6, 2015 and is uptrending. It has outperformed by 20.73% the S&P500.
The overall sentiment of institutions has increased to 0.91 in Q2 2015. Its up 0.24, from 0.67 in 2015Q2. The ratio is positive, as 61 institutions have sold all the shares of Eli Lilly and Co that they owned while 422 funds have taken shares off the table. 93 funds have purchased shares for the first time while 347 added to their positions. These institutions now hold 768.53 million shares or 7.90% less than the 834.48 million shares they owned in 2015Q2.
The Fund Lilly Endowment Inc currently is holding shares equating to 100% of its total portfolio in Eli Lilly and Co representing a total of 129.37 million shares. Another fund,Weatherly Asset Management L. P., is holding a total of 338,942 shares equating to 11.49% of their holdings. Additionally, March Altus Capital Management Lp has a 16,844 share stake in Eli Lilly and Co which represents 8.3% of their total portfolio. The Fund, Sector Gamma As, based out of Norway, has also built up a stake in the stock, which represents a total of 8.29% of their total portfolio. Finally Valueworks Llc, a fund which is based in the state of New York reported a total holdings of 93,833 shares.
Insider activity is a very important aspect to track on any stock. Going back to May 11, 2015, shareholders of Eli Lilly and Co have witnessed 0 insider purchases, and a total of 3 selling transactions equating to a net activity of approximately $63.20 million . Lilly Endowment Inc sold 215,000 shares worth approximately $18.46 million. Zakrowski Donald A sold 200 shares worth approximately $15,666. Simmons Jeffrey N sold 20,000 shares worth approximately $1.56M.
Eli Lilly and Company is engaged in drug manufacturing business. The company has a market cap of $95.72 billion. The Firm discovers, develops, makes and market products in two divisions: human pharmaceutical products and animal health products. It has 39.01 P/E ratio. The Company’s products are sold in approximately 120 countries.
According to Zacks Investment Research, “Eli Lilly and Company discovers, develops, manufactures, and sells products in one significant business segment -pharmaceutical products. The company directs its research efforts primarily toward the search for products to diagnose, prevent and treat human diseases. The company also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production.” Get a free copy of the Zacks research report on Eli Lilly and Co (LLY).